Capital – Talk Bio

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

1 week ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

3 weeks ago talkbio0Tagged Ayrmid, Bluebird Bio, Capital, Carlyle, Family Turdidae (organism), gene therapy, High, Twice a day

Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital

Sofinnova Partners Secures €1.2 Billion for Life Sciences Innovation

2 months ago talkbio0Tagged Capital, digital medicine, Health care facility, Industry, medtech, sustainability, venture

Venture capital, biotech, medtech, digital medicine, industrial biotech, healthcare, sustainability

Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation

2 months ago talkbio0Tagged Acquisition, Capital, Carlyle, DKK1 gene, Family Turdidae (organism), Financial Stress, gene therapy, Industry, Private Equity

Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry

New year starts with a bang as trio of venture financings brings in $382M

3 months ago talkbio0Tagged biotech, Capital, Investments, Life, Megarounds, Private financing, Tenvie, venture

Venture capital, Biotech funding, Megarounds, Tenvie Therapeutics, Private financing, Life sciences investments

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

3 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners